Key result
Metabolic syndrome increased the risk of major adverse events at 36 months after carotid endarterectomy or stenting compared to patients without it.
Why the study?
Does metabolic syndrome increase the risk of short- and long-term complications and restenosis in patients undergoing carotid endarterectomy or stenting?
Cohort (n=752)
No
Does metabolic syndrome increase the risk of short- and long-term complications and restenosis in patients undergoing carotid endarterectomy or stenting?
Answers are grounded in this paper and cite their sources.
The presence of metabolic syndrome is a significant risk factor for increased morbidity and restenosis up to 3 years following carotid endarterectomy or stenting.
AIMS: The metabolic syndrome (MetS) is composed of a cluster of related cardiovascular risk factors. The aim of the present study was to determine how MetS contributes to short- (30-day) and long-term complications and restenosis after carotid endarterectomy (CEA) or stenting (CAS). METHODS: A consecutive cohort of 752 patients undergoing CEA (n = 314) and CAS (n = 438) in a single institution was examined, of which 296 (39.4%) were identified as having MetS. All patients were followed-up with carotid duplex ultrasound scan of the supraaortic vessels and a neurological assessment of symptoms status at 30-day postprocedure and at 3, 6, and 12 months, with annual follow-up thereafter for 3 years. RESULTS: Patients with MetS had a significant increased risk in their 30-day death, major adverse events (MAE), and restenosis rates, both after CEA and after CAS (death: 0.7% vs 0.0%; MAE: 5.3% vs 2.7%; and restenosis: 1.7% vs 0.2%; p < 0.05). The MAE and restenosis rates remained statistically different at 36 months, with both procedures (29.2% vs 24.2% and 9.5% vs 3.3%, p < 0.05, for patients with and without MetS, respectively). Among the components of MetS, high fasting serum glucose, low high-density lipoprotein cholesterol, and elevated body mass index were associated with increased risk of complications at 30 days and within 36 months. CONCLUSIONS: The current study suggested that the presence of MetS is an important risk factor for morbidity and restenosis after CEA and CAS.
No takes yet. Share an insight, caveat, or question.
Casana et al. (2018) conducted a cohort in Patients undergoing carotid endarterectomy (CEA) or stenting (CAS) (n=752). Metabolic syndrome vs. Without metabolic syndrome was evaluated on Major adverse events (MAE) at 36 months (p=<0.05). Metabolic syndrome increased the risk of major adverse events at 36 months after carotid endarterectomy or stenting compared to patients without it.
Synapse has enriched 10 related papers. Consider them for comparative context: